Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Sareum Holdings plc    SAR   GB00B02RFS12

SAREUM HOLDINGS PLC

(SAR)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancials 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
11/30/2020 12/01/2020 12/02/2020 12/03/2020 12/04/2020 Date
1.5(c) 1.425(c) 1.45(c) 1.425(c) 1.444 Last
7 796 947 4 040 128 4 183 469 11 013 966 6 900 Volume
+5.26% -5.00% +1.75% -1.72% +1.33% Change
More quotes
Financials
Sales 2019 - - -
Net income 2019 -1,45 M -1,96 M -1,96 M
Net cash position 2019 0,92 M 1,24 M 1,24 M
P/E ratio 2019 -8,48x
Yield 2019 -
Sales 2020 0,05  0,06  0,06 
Net income 2020 -0,99 M -1,33 M -1,33 M
Net cash position 2020 1,80 M 2,43 M 2,43 M
P/E ratio 2020 -16,4x
Yield 2020 -
Capitalization 46,6 M 62,8 M 62,7 M
EV / Sales 2019 -
EV / Sales 2020 322x
Nbr of Employees 2
Free-Float 95,0%
More Financials
Company
Sareum Holdings plc is engaged in the discovery and development of new therapeutic drugs by a combination of skills in biology, computational chemistry and medicinal chemistry. The Company's drug programs include Checkpoint Kinase 1 (CHK1), Aurora+FLT3 Kinase and Tyrosine Kinase 2- autoimmune diseases (TYK2), Aurora+FLT3 kinase and TYK2 kinase-cancer. Its Chk1 program is the advanced program and shows potency in... 
Sector
Biotechnology & Medical Research
Calendar
12/15 | 05:00amShareholder meeting
More about the company
All news about SAREUM HOLDINGS PLC
12/03SAREUM : Covid-19 Research Grant Confirmed
PU
11/19SAREUM : Notice of AGM
PU
11/13SAREUM : Provides Update on Licensing Agreement Regarding SRA737, a Chk1 inhibit..
AQ
11/12SAREUM : Update on SRA737 Licensing Agreement
PU
10/20SAREUM : Exercise of Share Options and Director Dealings
PU
10/14SAREUM : Final results for the year ended 30 june 2020
AQ
10/13SAREUM : Full Year Results Investor Presentation
PU
10/13SAREUM : Final Results
PU
10/08US PATENT ALLOWANCE : SDC-1802 TYK2/JAK1 Inhibitor
PU
08/12SAREUM : Details of Investor Presentation
PU
08/11SAREUM : Trading Statement
PU
07/01SAREUM : Update on Deferred Salaries and Issue of Equity
PU
06/03SAREUM : Successful Fundraising
PU
06/02SAREUM : Placing to Raise £718,500
PU
05/27SAREUM : to Present at BIO Bigital 2020
PU
More news
News in other languages on SAREUM HOLDINGS PLC
2019SAREUM HOLDINGS PLC : -25% après un placement
More news
Chart SAREUM HOLDINGS PLC
Duration : Period :
Sareum Holdings plc Technical Analysis Chart | SAR | GB00B02RFS12 | MarketScreener
Technical analysis trends SAREUM HOLDINGS PLC
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Managers
NameTitle
Timothy John Mitchell Chief Executive Officer & Executive Director
Stephen B. Parker Non-Executive Chairman
John Charles Reader Executive Director & Chief Scientific Officer
Michael John Owen Non-Executive Director
Clive Birch Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
SAREUM HOLDINGS PLC301.41%63
GILEAD SCIENCES, INC.-6.34%76 628
VERTEX PHARMACEUTICALS3.62%58 951
REGENERON PHARMACEUTICALS32.85%53 359
WUXI APPTEC CO., LTD.67.28%39 880
BIONTECH SE250.30%29 157